Trial · NCT00981149
Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
NCT00981149, Not applicable, Completed, University of Maryland, Baltimore; results first posted 2017-11-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Duloxetine for Treatment of Painful Temporomandibular Joint Disorder. Trials, record NCT00981149. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00981149
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
- NCT number
- NCT00981149
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- University of Maryland, Baltimore
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- duloxetine, Placebo
- First posted
- 2009-09-22
- Last updated
- 2021-05-25
- Results first posted
- 2017-11-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | 1, 3, 6 weeks | Measurements from zero to 100 with 100 being the worst pain by Visual Analog Scale (VAS). |
| Secondary | Evoked Pain Via Algometry . | 6 weeks | Assessment of evoked pain using digital palpation examination at 18 predefined bodily sites. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | 1, 3, 6 weeks | units on a scale | MEAN | |
| SECONDARY | Evoked Pain Via Algometry . | 6 weeks | Pain pressure threshold (kg/cm2) | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Duloxetine Study Drug | 1 week | 42.9 | Standard Deviation 14.5 | units on a scale |
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Placebo | 1 week | 51.4 | Standard Deviation 19 | units on a scale |
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Duloxetine Study Drug | 3 weeks | 30.4 | Standard Deviation 18 | units on a scale |
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Placebo | 3 weeks | 44 | Standard Deviation 25 | units on a scale |
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Duloxetine Study Drug | 6 weeks | 34.8 | Standard Deviation 23.7 | units on a scale |
| Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. | Placebo | 6 weeks | 36.7 | Standard Deviation 26 | units on a scale |
| Evoked Pain Via Algometry . | Duloxetine Study Drug | 311.9 | Standard Deviation 115.8 | Pain pressure threshold (kg/cm2) | |
| Evoked Pain Via Algometry . | Placebo | 300.8 | Standard Deviation 80.9 | Pain pressure threshold (kg/cm2) |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Duloxetine Study Drug | 12 | |
| Overall Study | STARTED | Placebo | 12 | |
| Overall Study | COMPLETED | Duloxetine Study Drug | 10 | |
| Overall Study | COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | Duloxetine Study Drug | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | General disorders | Duloxetine Study Drug | 10 | 10 | |
| other | Headache | General disorders | Placebo | 9 | 9 | |
| other | Osteoarthritis | Musculoskeletal and connective tissue disorders | Duloxetine Study Drug | 10 | 10 | |
| other | Osteoarthritis | Musculoskeletal and connective tissue disorders | Placebo | 9 | 9 | |
| other | Fibromyalgia | Musculoskeletal and connective tissue disorders | Duloxetine Study Drug | 10 | 10 | |
| other | Fibromyalgia | Musculoskeletal and connective tissue disorders | Placebo | 9 | 9 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Duloxetine Study Drug | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Duloxetine Study Drug | 10 | 10 |
| Total, other adverse events | Placebo | 9 | 9 |
| Total, serious adverse events | Duloxetine Study Drug | 0 | 10 |
| Total, serious adverse events | Placebo | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Duloxetine Study Drug vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00981149
GET https://conductscience.org/api/trials/v1/NCT00981149/registered